Kazia Therapeutics can boast six ongoing clinical trials, all under the oversight of the US FDA, aimed at addressing some of the world's most challenging cancers.
Paxalisib (formerly GDC-0084) inhibits the PI3K pathway that is thought to be critical to the development of certain kinds of tumours. Paxalisib is currently involved in five clinical trials examining our drug in a range of forms of brain cancer including:
Glioblastoma - the most common and most aggressive form of primary brain cancer
DIPG - a rare but very aggressive childhood brain cancer
Breast cancer brain metastises (BCBM)
Two separate trials focussed on cancer which has spread to the brain from any primary source
Cantrixil (TRE-E-002-1) is a third-generation benzopyran that targets slower dividing 'tumour-initiating cells' thereby helping combat the problems of resistance and recurrence that occur with chemotherapy. We are currently in a Phase I study in ovarian cancer, and have recently completed recruitment to Part B of this trial.